No Data
NeuroSense Announces PARADIGM Study Results Showing PrimeC Slows ALS Progression By 33% And Improves Survival By 58%, Redefining Potential Standard Of Care In ALS Treatment
NeuroSense Therapeutics Announces Securities Purchase Agreement
Connection With The Offering, NeuroSense Agreed To Sell An Aggregate Of 4M Ordinary Shares And 8M Warrants To Purchase An Aggregate Of 8M Ordinary Shares, At A Combined Purchase Price Of $1.25 Per Share And 2 Accompanying Warrants
NeuroSense Therapeutics Announces Agreement With CEO Alon Ben-Noon To Purchase Aggregate Of $5M Ordinary Shares And Warrants In A Private Placement
Express News | Neurosense Therapeutics Announces $5 Million Private Placement at Premium to Market Price
Press Release: NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price
No Data
No Data